Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

03 September 2007

Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis c recurrence following combined liver and kidney transplantation

Volker Schmitz, Anja Kiessling, Marcus Bahra, Gero Puhl, Andreas Kahl, Thomas Berg, Ruth Neuhaus, Peter Neuhaus, Ulf Neumann

Ann Transplant 2007; 12(3): 22-27 :: ID: 546215

Abstract

Background: Several studies have demonstrated safety and effi cacy of treatment protocols using pegylated interferon alfa-2b (PegIntron®) and ribavirin in hepatitis C (HCV) recurrence and liver transplantation but no data exists about antiviral treatment following combined liver and kidney transplantation.
Patients: Six patients with recurrent HCV (genotype 1 [n=5] and 4 [n=1]) received peginterferon alfa-2b (1 ug/kg/weekly) and ribavirin (600 mg) for 48 weeks. Sustained virologic response was defi ned as undetectable HCV-RNA 24 weeks after termination of therapy. All patients underwent liver biopsies prior to treatment and after 72 weeks and liver enzymes (ASAT) and serum creatinine levels were obtained regularly.
Results: In 4/6 patients, viral load prior to treatment was below 1,000,000 (IU/mL). SVR was achieved in 3/6 (50%) patients. None of the patients developed signs of deteriorating kidney function or rejection. One patient without SVR had HCV related liver graft failure and died 13 months later. Side effects like neutropenia (50%) and anemia (50%) were treated with G-CSF, erythropoietin, and dose reduction of peginterferon and ribavirin.
Conclusions: In a small group of patients with combined kidney and liver transplantation, peginterferon-alfa2b is safe and effective to achieve SVR in HCV recurrence. Larger scale studies are warranted to further validate our results.

Keywords: Liver Kidney Transplantation, Recurrent Hepatitis C, pegylated interferon

Add Comment 0 Comments

Most Viewed Current Articles

15 Aug 2023 : Review article   7,252

Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ Transplantation

DOI :10.12659/AOT.939750

Ann Transplant 2023; 28:e939750

03 Jan 2023 : Original article   7,143

Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and...

DOI :10.12659/AOT.938467

Ann Transplant 2023; 28:e938467

16 May 2023 : Original article   6,944

Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections ...

DOI :10.12659/AOT.939258

Ann Transplant 2023; 28:e939258

28 May 2024 : Original article   6,443

Effect of Dexmedetomidine Combined with Remifentanil on Emergence Agitation During Awakening from Sevoflura...

DOI :10.12659/AOT.943281

Ann Transplant 2024; 29:e943281

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358